by: Parent Project Muscular Dystrophy
Dyne Therapeutics recently joined PPMD for a presentation of clinical data from the DELIVER Trial of DYNE-251 in individuals living with Duchenne muscular dystrophy who are amenable to exon 51 skipping, first released on May 20th, 2024.
Dyne’s Chief Medical Affairs Officer and VP of Global Patient Advocacy shared insights on how these data demonstrated compelling impact on key disease biomarkers and trends in improvement of multiple functional endpoints. The session also includes a Q&A portion where Dyne addresses questions from the community.
